StockNews.com Lowers Omeros (NASDAQ:OMER) to Sell

StockNews.com downgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report issued on Tuesday morning.

Omeros Trading Up 0.9 %

NASDAQ OMER opened at $3.45 on Tuesday. The company has a 50 day moving average price of $3.90 and a 200 day moving average price of $2.97. The firm has a market cap of $216.90 million, a PE ratio of 10.78 and a beta of 1.38. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 10.80. Omeros has a 52 week low of $0.92 and a 52 week high of $7.80.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently modified their holdings of OMER. BlackRock Inc. increased its stake in Omeros by 258.0% during the 2nd quarter. BlackRock Inc. now owns 4,154,952 shares of the biopharmaceutical company’s stock valued at $22,603,000 after purchasing an additional 2,994,468 shares in the last quarter. State Street Corp increased its position in shares of Omeros by 344.7% in the 2nd quarter. State Street Corp now owns 1,139,199 shares of the biopharmaceutical company’s stock valued at $6,197,000 after acquiring an additional 883,025 shares during the period. Millennium Management LLC raised its stake in Omeros by 188.1% in the 2nd quarter. Millennium Management LLC now owns 1,220,782 shares of the biopharmaceutical company’s stock worth $3,357,000 after acquiring an additional 797,034 shares during the last quarter. CI Private Wealth LLC acquired a new stake in Omeros during the 4th quarter worth about $1,453,000. Finally, Geode Capital Management LLC increased its holdings in shares of Omeros by 98.4% in the second quarter. Geode Capital Management LLC now owns 1,253,711 shares of the biopharmaceutical company’s stock valued at $6,820,000 after purchasing an additional 621,819 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.